Diagnosis and graft characteristics
. | No. . |
|---|---|
| N | 23 |
| Diagnosis, no.(%) | |
| ALL | |
| CR1 | 4 (17) |
| CR2 | 1 (4) |
| Relapse | 3 (13) |
| AML* | |
| CR1 | 4 (17) |
| CR2 | 3 (13) |
| CR3 | 1 (4) |
| MDS | 1 (4) |
| Relapse | 4 (17) |
| CML | |
| CP1 | 1 (4) |
| AP1 | 1 (4) |
| Infused NC × 107/kg, median (range) | |
| Total | 3.5 (1.1-6.3) |
| Larger unit | 1.9 (0.6-3.6) |
| Smaller unit | 1.5 (0.5-2.7) |
| Infused CD34+ × 105/kg, median (range) | |
| Total | 4.9 (1.2-14.5) |
| Larger unit | 2.9 (0.7-10.4) |
| Smaller unit | 1.4 (0.5-4.7) |
| Infused CD3+ × 107/kg, median (range) | |
| Total | 1.0 (0.5-2.2) |
| Larger unit | 0.6 (0.3-1.3) |
| Smaller unit | 0.4 (0.1-0.9) |
. | No. . |
|---|---|
| N | 23 |
| Diagnosis, no.(%) | |
| ALL | |
| CR1 | 4 (17) |
| CR2 | 1 (4) |
| Relapse | 3 (13) |
| AML* | |
| CR1 | 4 (17) |
| CR2 | 3 (13) |
| CR3 | 1 (4) |
| MDS | 1 (4) |
| Relapse | 4 (17) |
| CML | |
| CP1 | 1 (4) |
| AP1 | 1 (4) |
| Infused NC × 107/kg, median (range) | |
| Total | 3.5 (1.1-6.3) |
| Larger unit | 1.9 (0.6-3.6) |
| Smaller unit | 1.5 (0.5-2.7) |
| Infused CD34+ × 105/kg, median (range) | |
| Total | 4.9 (1.2-14.5) |
| Larger unit | 2.9 (0.7-10.4) |
| Smaller unit | 1.4 (0.5-4.7) |
| Infused CD3+ × 107/kg, median (range) | |
| Total | 1.0 (0.5-2.2) |
| Larger unit | 0.6 (0.3-1.3) |
| Smaller unit | 0.4 (0.1-0.9) |
ALL indicates acute lymphoblastic leukemia; CR, complete remission; AML, acute myelogenous leukemia; MDS, myelodysplasia; CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; and NC, nucleated cell.
Patients with AML in CR1 had disease secondary to prior myelodysplasia. MDS refers to recurrent MDS after AML induction